Medison Biotech: Jonathan Goodman takes advantage of his own failure to create value, enriching himself at the expense of the shareholders of Knight Therapeutics

NCIB introduced by Knight proposes to buy back shares from shareholders at a 25% discount compared to last capital raise in 2016 of $10 per share

By doing so, Goodman admits that the last raise was excessive, a mistake and that he has no concrete plans or strategy to deploy the raised cash

This move is yet another acknowledgement of Knight’s failure following the recent admission that the $130 million committed to its “investments in funds” strategy failed

read more

Medison Issues Open Letter to Knight Therapeutics Shareholders Urging Jonathan Goodman to Build Real Business during the Grace Period Knight Received

PETACH TIKVA, Israel, June 19, 2019 – Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”), today issued the following open letter from Medison CEO Meir Jakobsohn on Knight’s continued underperformance and conflicts of interest:

read more

Medison Creates Significant Change at Knight Therapeutics

Medison’s campaign created unanimous consent that an immediate change is required at Knight and also a collective demand from shareholders that Knight’s leadership create near term value and increase the share price Medison's campaign “rocked the boat” and made Knight...

read more

Stay Informed

Enter your info below to stay up-to-date.